AI Article Synopsis

  • Long-lasting CD4 T cells infected with HIV pose a major challenge for finding a cure, as they can survive even with long-term antiretroviral therapy (ART).
  • Inducing HIV from its latent state could help reduce the viral reservoir faster, but previous efforts focused mainly on blood rather than tissue sites and showed limited success.
  • The study demonstrates that activating the non-canonical NF-κB pathway with AZD5582 effectively triggers HIV expression in multiple tissues, enhancing potential strategies for HIV eradication when combined with treatments for viral clearance.

Article Abstract

Long-lasting, latently infected resting CD4 T cells are the greatest obstacle to obtaining a cure for HIV infection, as these cells can persist despite decades of treatment with antiretroviral therapy (ART). Estimates indicate that more than 70 years of continuous, fully suppressive ART are needed to eliminate the HIV reservoir. Alternatively, induction of HIV from its latent state could accelerate the decrease in the reservoir, thus reducing the time to eradication. Previous attempts to reactivate latent HIV in preclinical animal models and in clinical trials have measured HIV induction in the peripheral blood with minimal focus on tissue reservoirs and have had limited effect. Here we show that activation of the non-canonical NF-κB signalling pathway by AZD5582 results in the induction of HIV and SIV RNA expression in the blood and tissues of ART-suppressed bone-marrow-liver-thymus (BLT) humanized mice and rhesus macaques infected with HIV and SIV, respectively. Analysis of resting CD4 T cells from tissues after AZD5582 treatment revealed increased SIV RNA expression in the lymph nodes of macaques and robust induction of HIV in almost all tissues analysed in humanized mice, including the lymph nodes, thymus, bone marrow, liver and lung. This promising approach to latency reversal-in combination with appropriate tools for systemic clearance of persistent HIV infection-greatly increases opportunities for HIV eradication.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111210PMC
http://dx.doi.org/10.1038/s41586-020-1951-3DOI Listing

Publication Analysis

Top Keywords

hiv siv
12
induction hiv
12
hiv
10
non-canonical nf-κb
8
nf-κb signalling
8
resting cd4
8
cd4 cells
8
siv rna
8
rna expression
8
humanized mice
8

Similar Publications

Broadly neutralizing antibodies (bnAbs) against HIV-1 have been shown to protect from systemic infection. When employing a novel challenge virus that uses HIV-1 Env for entry into target cells during the first replication cycle, but then switches to SIV Env usage, we demonstrated that bnAbs also prevented mucosal infection of the first cells. However, it remained unclear whether antibody Fc-effector functions contribute to this sterilizing immunity.

View Article and Find Full Text PDF

Previously obtained highly immunogenic Env-VLPs ensure overcoming the natural resistance of HIV-1 surface proteins associated with their low level of incorporation and inaccessibility of conserved epitopes to induce neutralizing antibodies. We also adopted this technology to modify Env trimers of the ZM53(T/F) strain to produce Env-VLPs by recombinant vaccinia viruses (rVVs). For VLP production, rVVs expressing Env, Gag-Pol (HIV-1/SIV), and the cowpox virus hr gene, which overcomes the restriction of vaccinia virus replication in CHO cells, were used.

View Article and Find Full Text PDF

eCD4-immunoglobulin (Ig) is an HIV entry inhibitor that mimics the engagement of both CD4 and CCR5 with the HIV envelope (Env) protein, a property that imbues it with remarkable potency and breadth. However, env is exceptionally genetically malleable and can evolve to escape a wide variety of entry inhibitors. Here we document the evolution of partial eCD4-Ig resistance in SHIV-AD8-infected rhesus macaques (RMs) treated with adeno-associated virus vectors encoding eCD4-Ig.

View Article and Find Full Text PDF

Deubiquitinase USP37 enhances the anti-HIV-2/SIV ability of the host restriction factor SAMHD1.

J Virol

December 2024

Center of Infectious Diseases and Pathogen Biology, Institute of Virology and AIDS Research, Key Laboratory of Organ Regeneration and Transplantation of The Ministry of Education, The First Hospital of Jilin University, Changchun, China.

The Vpx protein encoded by HIV-2/simian immunodeficiency virus (SIV) can antagonize the restriction of the host intrinsic restriction factor, SAMHD1, in nondividing cells by promoting its polyubiquitination and subsequent degradation, thereby facilitating viral replication and immune evasion. However, the role of deubiquitinating enzymes (DUBs) in the dynamics of virus and host remains poorly understood. Here, we demonstrate that DUB USP37 significantly reverses the Vpx-mediated degradation of SAMHD1 in various HIV-2/SIV subtypes by interacting with SAMHD1 and removing its ubiquitin chains.

View Article and Find Full Text PDF
Article Synopsis
  • * It finds that the frequency of SIV-Gag-specific follicular CD8 T cells is linked to the amount of SIV-RNA, particularly in treated or naturally controlling macaques, while showing a different behavior in untreated macaques.
  • * The research indicates that the gene expression profile of fCD8 T cells in naturally controlled infections is more favorable compared to those under cART, suggesting that improving these cells may lead to potential curative strategies for HIV/SIV.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!